Literature DB >> 12469143

Expression of survivin and matrix metalloproteinases in adenocarcinoma and squamous cell carcinoma of the uterine cervix.

Hiroyuki Yoshida1, Toshiyuki Sumi, Yooji Hyun, Eri Nakagawa, Kanae Hattori, Tomoyo Yasui, Mina Morimura, Ken-Ichi Honda, Tatsuya Nakatani, Osamu Ishiko.   

Abstract

Cervical cancer can be classified into two histological types: squamous cell carcinoma (SCA) and adenocarcinoma (ACA). Reportedly ACA has poorer prognoses, metastasizes more easily to lymph nodes, and is more resistant to radiotherapy than SCA. To clarify the cause of characteristic differences between these histological types, we examined the expressions of apoptosis inhibiting and tumor-invasion related factors in both histological types. We reviewed the 34 cases of cervical cancer (17 ACA, 17 SCA) that had surgery as their initial treatment at Osaka City University Medical School Hospital between 1996 and 2001. The differences of survivin, and matrix metalloproteinase (MMP-2, and MMP-7) expressions between both histological types were immunohistochemically assayed, and the correlation between the expression of each protein and clinicopathological characteristics was analyzed. Survivin was expressed significantly stronger in ACA cases (p=0.035). The number of patients who expressed MMP-2 and MMP-7 simultaneously was significantly higher in SCA cases (p=0.039). MMP-2 and MMP-7 had tendencies to be expressed stronger in SCA (p=0.057 and p=0.084, respectively). These results suggest that the differences of the expression of survivin (an apoptosis inhibiting factor), MMP-2, and MMP-7 (tumor-invasion related factors) between ACA and SCA were causes of the characteristic differences between the two histological types.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12469143

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Survivin promoter polymorphism and cervical carcinogenesis.

Authors:  A A Borbély; M Murvai; K Szarka; J Kónya; L Gergely; Z Hernádi; G Veress
Journal:  J Clin Pathol       Date:  2006-05-19       Impact factor: 3.411

Review 2.  Current developments in adenovirus-based cancer gene therapy.

Authors:  Daniel T Rein; M Breidenbach; David T Curiel
Journal:  Future Oncol       Date:  2006-02       Impact factor: 3.404

3.  Evaluating the number of stages in development of squamous cell and adenocarcinomas across cancer sites using human population-based cancer modeling.

Authors:  Julia Kravchenko; Igor Akushevich; Amy P Abernethy; H Kim Lyerly
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

4.  Inhibitors of apoptosis proteins in human cervical cancer.

Authors:  Magali Espinosa; David Cantú; Norma Herrera; Carlos M Lopez; Jaime G De la Garza; Vilma Maldonado; Jorge Melendez-Zajgla
Journal:  BMC Cancer       Date:  2006-02-27       Impact factor: 4.430

5.  Correlations of polymorphisms in matrix metalloproteinase-1, -2, and -7 promoters to susceptibility to malignant gliomas.

Authors:  Priyanka Kawal; Anil Chandra; Tapan N Dhole; Balkrishna Ojha
Journal:  Asian J Neurosurg       Date:  2016 Apr-Jun

Review 6.  Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma.

Authors:  Zakir Khan; Abdul Arif Khan; Hariom Yadav; Godavarthi B K S Prasad; Prakash Singh Bisen
Journal:  Cell Mol Biol Lett       Date:  2017-04-05       Impact factor: 5.787

7.  Antitumor effects of nadroparin combined with radiotherapy in Lewis lung cancer models.

Authors:  Xibing Zhuang; Tiankui Qiao; Sujuan Yuan; Qi Zhang; Wei Chen; Youjun Luo; Guoxiong Xu
Journal:  Onco Targets Ther       Date:  2018-08-24       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.